Vivos Therapeutics Secures $100M Term Loan Facility Amendment, Draws $60M

Why It Matters

The new reimbursement code and large‑scale trial remove key adoption barriers, positioning Vivos to capture a sizable share of the under‑penetrated heart‑failure device market and drive sustainable revenue growth.

Key Takeaways

• Q4 revenue $16M, up 4%; FY $56.7M, +410%
• Gross margin 86%, improved pricing and efficiencies
• Category I CPT code lifts reimbursement, prior auth 46%
• BENEFIT HF trial starts, 2,500 patients, $30B market
• Salesforce now 53 US territories, 252 active implant centers

Pulse Analysis

Vivos Therapeutics’ latest earnings call underscores a pivotal shift from pure revenue growth to building a commercial engine capable of scaling Barostim adoption. By expanding its U.S. footprint to 53 territories and adding 252 active implant centers, the company is creating a dense network that enables "same‑store" growth—higher implant rates at existing sites—while still pursuing geographic expansion. This territory‑focused model, coupled with targeted training and a narrowed account list, mirrors best‑in‑class strategies seen in other med‑tech firms that have successfully transitioned from niche products to mainstream therapies.

The regulatory milestones announced—Category I CPT coding and CMS Category B IDE coverage—directly address the two biggest hurdles for device uptake: reimbursement certainty and prior‑authorization friction. The CPT upgrade standardizes physician payment at roughly $560 per implant and eliminates automatic denials, which already lifted Medicare Advantage approval rates to 46% from 31% a year earlier. Such payer confidence not only accelerates adoption in high‑volume centers but also encourages smaller hospitals to add Barostim to their heart‑failure portfolios, expanding the addressable patient pool.

Perhaps the most consequential development is the launch of the BENEFIT HF trial, a 2,500‑patient, multinational study that could triple Vivos’ prevalence‑based market from 339,000 to over 980,000 patients, translating to a $30 billion opportunity. Successful trial outcomes would provide robust clinical evidence, further easing payer negotiations and solidifying Barostim’s role alongside guideline‑directed medical therapy. Combined with a $86 million capital runway and an amended $100 million term loan, Vivos appears well‑positioned to fund commercial rollout and R&D while avoiding equity dilution, a narrative that should resonate with investors seeking growth backed by sustainable cash flow.

Deal Summary

Vivos Therapeutics Inc announced that its term loan facility was amended in January 2026, raising the commitment to $100 million and drawing $60 million at closing, with the maturity extended to 2031. The amendment provides additional non‑dilutive capital to support its 2026 growth initiatives and clinical trial funding. This debt financing is part of the company’s broader capital strategy.